Mouse anti Human CD2 FITC - CD7 PECatalog number: 0027
Bi-Test™ Reagents (FITC/RPE)
Identification of human T cells and subset of NK cells associated with the receptor for sheep erythocytes rosettes expressing the 45-50,000 M.W. surface antigen. Identification of human T lymphocytes in multiple stages of T cell development, including a major subset of mature peripheral T cell. CD7 antigen is often increased on T leukemic cells. The CD7 molecule is a 40,000 M.W. surface antigen that is expressed on T-Lymphoid and myeloid precursors in fetal liver and bone marrow.
Synonyms: CD2 FITC - CD7 PE
Immunogen: CD2=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with t lymphocytes activated by mixed lymphocyte culture. CD7=Derived from the hybridization of mouse P3-X63-Ag8.653 myeloma cells with spleen cells of BALB/c mice immunized with T-acute lymphoblastic leukemia (T-ALL) cells.
Product Form: Bi-Test (FITC/RPE) Reagent
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Purification Method: Protein A/G Chromatography
Concentration: Titered for flow cytometry
PBMC: Add10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2º to 8ºC. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add10 µl of MAB /100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20ºC. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer’s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
Functional Analysis: Flow Cytometry Staining
Product should be stored at 4-8ºC. DO NOT FREEZE
Product Stability: See expiration date on vial
Shipping Conditions: Ship at ambient temperature, do not freeze, refrigerate upon arrival
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1.An Improved Rosetting Assay for Detection of Human T Lymphocytes. Kaplan M.E., Clark C., J. Immunol. Methods 1974, 5,131 2.Structural and functional characterization of the CD2 immunoadhesion domain. Evidence for inclusion of CD2 in an alpha-beta protein folding class. Recny M.A., Neidhardt E.A., Sayre P.H., Ciardelli T.L., Reinherz E.L., J. Biol. Chem. 1990 May 2;265(15):85419 3. Partial deletions of the cytoplasm domain of CD2 result in a partial defect in signal transduction. Bierer B.E., Bogart R.E., Burakoff S.J., J. Immunol. 1990 Feb. :144(3):785 4. Functional CD2 mutants unable to bind to, or be stimulated by, LFA-3. Wolff H.L., Burakoff S.J., Bierer B.E., J. Immunol. 1990 Feb. 1;144(4):1215-20 5. Association of CD2 and CD45 on human T lymphocytes. Schraven B., Samstag Y., Altevogt P., Meuer S.C., Nature 1990 May ;345(6270):71-4 6. Isolation and characterization of the genomic human CD7 gene: structural similarity with the murine Thy-1 gene. Schanberg LE, Fleener DE, Kurtzberg J, Haynes BF, Kaufman RE; Proc Natl Acad Sci USA 1991 Jan 1;88(2):603-7 7. Identification of novel B-lineage cells in human fetal bone marrow that coexpress CD7. Grumayer ER, Griesinger F, Hummell DS, Brunning RD, Kersey JH; Blood 1991 Jan ; 77(1):64-8 8. Genuine CD7 expression in acute leukemic and lymphoblastic lymphoma. Osada H, Emi N, Ueda R, Seto M, Koike K, Suchi T, Kojima S, Obata Y, Takahashi T; Leuk Res 1990;14(10):869-77 9. Inhibition of alloresponsive naive and memory T cells by CD7 and CD25 antibodies and by cyclosporine. Akbar An, Amlot PL, Ivory K, Timms A, Janossy G; Transplantation 1990 No;50(5):823-9 10. Comparsion of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. Garand R, Vannier JP, Bene MC, Faure G, Favre M, Bernard A; Leukemic 1990 No;4(11):739-44
Database Name: UniProt
Accession Number: P06729, P09564
Safety Datasheet(s) for this product: